Hexarelin
The most potent GHRP in terms of GH peak — also has direct cardiac protective effects via CD36 receptor, independent of GH.
Research facts
| Half-life | ~2–3h |
|---|---|
| Route | SubQ / IV |
| Typical dose | 100–200 mcg |
| Frequency | 2–3× daily |
| Solvent | Bacteriostatic water |
| pH | 5.5–7.5 |
| Stability | 30 days at +4°C |
Mechanism of action
Hexarelin is the most potent GHRP in terms of GH pulse amplitude — achieving higher peak GH than GHRP-2, GHRP-6, or Ipamorelin at equivalent doses. Like other GHRPs, it activates GHS-R1a. However, hexarelin also binds the scavenger receptor CD36 on cardiac myocytes and macrophages, producing cardioprotective effects independent of GH or IGF-1. This direct cardiac action (anti-apoptotic, anti-inflammatory in cardiac tissue) has been demonstrated in multiple animal models of myocardial infarction and heart failure. Human Phase I/II data exist primarily for its GH-stimulatory effects.
Documented effects (research-model)
- Highest GH pulse amplitude among GHRPs
- Cardioprotection via CD36 receptor (independent of GH)
- Anti-apoptotic effects in cardiac myocytes
- Phase II human GH deficiency data
- Research tool for cardiac protection models
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Standard | 100–200 mcg SubQ | 2–3× daily | 8–12 weeks | 5mg / 5mL BAC water |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- CJC-1295 HIGH
GHRH + GHRP synergy. Hexarelin's extreme GH peak is further amplified by GHRH co-administration.
Myths & misconceptions
Evidence gaps
- Desensitisation occurs faster with hexarelin than other GHRPs — unclear optimal cycle length.
- Human cardiac protection trials not yet completed.
- Cortisol and prolactin co-stimulation at high doses.
Safety notes
Rapid receptor desensitisation — efficacy decreases with chronic daily use more than other GHRPs. Cortisol and prolactin elevation. Monitor all GH-axis markers plus cardiac function in research protocols.
Biomarkers to monitor
Primary-source citations
- PMID 15456933 — Hexarelin protects against ischaemic myocardial damage via CD36 receptor (Eur J Pharmacol. 2004)
Frequently asked
What is Hexarelin?
Hexarelin (Examorelin — Most Potent GHRP) is a research compound classified in our library as Tier B — Some human data + strong preclinical evidence.. The most potent GHRP in terms of GH peak — also has direct cardiac protective effects via CD36 receptor, independent of GH.
What is the evidence tier for Hexarelin?
We classify Hexarelin as Tier B: Some human data + strong preclinical evidence. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of Hexarelin?
For Hexarelin, typical research dose is 100–200 mcg, route is SubQ / IV, half-life is ~2–3h. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
What does Hexarelin stack well with?
Hexarelin stacks well with CJC-1295. GHRH + GHRP synergy. Hexarelin's extreme GH peak is further amplified by GHRH co-administration.
Is Hexarelin safe?
Rapid receptor desensitisation — efficacy decreases with chronic daily use more than other GHRPs. Cortisol and prolactin elevation. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.